ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

PARSABIV
Secondary hyperparathyroidism or hypocalcemia
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

PARSABIV Rx

Generic Name and Formulations:
Etelcalcetide 2.5mg/0.5mL, 5mg/mL, 10mg/2mL; soln for IV inj; preservative-free.

Company:
Amgen, Inc.

Therapeutic Use:

Indications for PARSABIV:

Secondary hyperparathyroidism in adults with chronic kidney disease (CKD) on hemodialysis.

Limitations Of use:

Not recommended in adults with parathyroid carcinoma, primary hyperparathyroidism, or with CKD who are not on hemodialysis.

Adult:

Give at the end of hemodialysis. Initially 5mg as IV bolus inj 3 times weekly. Maintenance: 2.5mg–15mg 3 times weekly based on PTH target range and corrected serum calcium response within normal range. May increase in 2.5mg or 5mg increments no sooner than every 4 weeks; max 15mg 3 times weekly. Monitoring and dose adjustment: see full labeling. Switching from cinacalcet: initially 5mg.

Children:

Not established.

Warnings/Precautions:

Hypocalcemia: may increase risk of QT prolongation and ventricular arrhythmias in congenital or family history of long QT syndrome or sudden cardiac death, history of QT prolongation and other predispositions; monitor closely. Seizure disorders. Measure corrected serum calcium prior to initiation; do not start if below lower limit of normal. Monitor serum calcium within 1 week of initiation or dose adjustment and every 4 weeks during treatment (see full labeling). If serum calcium is below lower limit of normal or symptoms of hypocalcemia occurs, initiate or increase calcium supplementation. Monitor for adynamic bone disease; if PTH levels fall below target range, reduce dose (Vit.D sterols and/or etelcalcetide) or discontinue; resume at lower dose. Monitor closely for worsening heart failure. Known gastritis, esophagitis, ulcers, severe vomiting: monitor for worsening GI reactions, bleeding, and ulcerations. Pregnancy. Nursing mothers: not recommended.

Interactions:

See Adults. Risk of severe hypocalcemia with concomitant other oral calcium-sensing receptor agonist. When switching from cinacalcet, discontinue cinacalcet for at least 7 days prior to initiation.

Pharmacological Class:

Calcimimetic.

Adverse Reactions:

Decreased blood calcium, muscle spasms, diarrhea, nausea, vomiting, headache, hypocalcemia (may be severe), paresthesia.

Generic Availability:

NO

How Supplied:

Single-dose vials—10

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs